Literature DB >> 22888134

Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Jacqueline A Quandt1, Jaebong Huh, Mirza Baig, Karen Yao, Naoko Ito, Mark Bryant, Kazuyuki Kawamura, Clemencia Pinilla, Henry F McFarland, Roland Martin, Kouichi Ito.   

Abstract

Genetic susceptibility to multiple sclerosis (MS) has been linked to the HLA-DR15 haplotype consisting of DRB1*15:01(DR2b) and DRB5*01:01(DR2a) alleles. Given almost complete linkage disequilibrium of the two alleles, recent studies suggested differential roles in susceptibility (DR2b) or protection from MS (DR2a). Our objective was to assess the potential contribution of DR2a to disease etiology in MS using a humanized model of autoimmunity. To assess the potential contribution of DR2a to disease etiology, we created DR2a humanized transgenic (Tg) mice and subsequently crossed them to Tg mice expressing TL3A6, an MS patient-derived myelin basic protein 83-99-specific TCR. In TL3A6/DR2a Tg mice, CD4 Tg T cells escape thymic and peripheral deletion and initiate spontaneous experimental autoimmune encephalomyelitis (EAE) at low rates, depending on the level of DR2a expression. The ability to induce active EAE was also increased in animals expressing higher levels of DR2a. Inflammatory infiltrates and neuronal damage were present throughout the spinal cord, consistent with a classical ascending EAE phenotype with minor involvement of the cerebellum, brainstem, and peripheral nerve roots in spontaneous, as well as actively induced, disease. These studies emphasize the pathologic contribution of the DR2a allele to the development of autoimmunity when expressed as the sole MHC class II molecule, as well as strongly argue for DR2a as a contributor to the CNS autoimmunity in MS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22888134      PMCID: PMC3436970          DOI: 10.4049/jimmunol.1103087

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries.

Authors:  C Pinilla; J R Appel; P Blanc; R A Houghten
Journal:  Biotechniques       Date:  1992-12       Impact factor: 1.993

2.  Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules.

Authors:  Y K Chou; M Vainiene; R Whitham; D Bourdette; C H Chou; G Hashim; H Offner; A A Vandenbark
Journal:  J Neurosci Res       Date:  1989-06       Impact factor: 4.164

3.  Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.

Authors:  R Martin; D Jaraquemada; M Flerlage; J Richert; J Whitaker; E O Long; D E McFarlin; H F McFarland
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

4.  Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals.

Authors:  M Pette; K Fujita; B Kitze; J N Whitaker; E Albert; L Kappos; H Wekerle
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

5.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

Authors:  M Pette; K Fujita; D Wilkinson; D M Altmann; J Trowsdale; G Giegerich; A Hinkkanen; J T Epplen; L Kappos; H Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106.

Authors:  R Martin; U Utz; J E Coligan; J R Richert; M Flerlage; E Robinson; R Stone; W E Biddison; D E McFarlin; H F McFarland
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

7.  Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

Authors:  A Valli; A Sette; L Kappos; C Oseroff; J Sidney; G Miescher; M Hochberger; E D Albert; L Adorini
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

8.  CD69 cell surface expression identifies developing thymocytes which audition for T cell antigen receptor-mediated positive selection.

Authors:  I Yamashita; T Nagata; T Tada; T Nakayama
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

9.  A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis.

Authors:  R Martin; M D Howell; D Jaraquemada; M Flerlage; J Richert; S Brostoff; E O Long; D E McFarlin; H F McFarland
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

10.  Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.

Authors:  K W Wucherpfennig; A Sette; S Southwood; C Oseroff; M Matsui; J L Strominger; D A Hafler
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  15 in total

1.  T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates.

Authors:  Blake M Callahan; Wei Lue Tong; George Blanck
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

2.  Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.

Authors:  Lisa E Creary; Kalyan C Mallempati; Sridevi Gangavarapu; Stacy J Caillier; Jorge R Oksenberg; Marcelo A Fernández-Viňa
Journal:  Mult Scler       Date:  2018-04-23       Impact factor: 6.312

3.  Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.

Authors:  Sarah Neil; Jaebong Huh; Victoria Baronas; Xinhui Li; Henry F McFarland; Murali Cherukuri; James B Mitchell; Jacqueline A Quandt
Journal:  Brain Behav Immun       Date:  2017-02-24       Impact factor: 7.217

4.  A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data?

Authors:  Kerrie Vaughan; Bjoern Peters; Kevin C O'Connor; Roland Martin; Alessandro Sette
Journal:  J Neuroimmunol       Date:  2013-12-12       Impact factor: 3.478

5.  Gut dysbiosis breaks immunological tolerance toward the central nervous system during young adulthood.

Authors:  Sudhir K Yadav; Sridhar Boppana; Naoko Ito; John E Mindur; Martin T Mathay; Ankoor Patel; Suhayl Dhib-Jalbut; Kouichi Ito
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-16       Impact factor: 11.205

Review 6.  DNA Methylation: a New Player in Multiple Sclerosis.

Authors:  Xiang Li; Bing Xiao; Xing-Shu Chen
Journal:  Mol Neurobiol       Date:  2016-06-17       Impact factor: 5.590

7.  Tolerogenic vaccines for Multiple sclerosis.

Authors:  Mark D Mannie; Alan D Curtis
Journal:  Hum Vaccin Immunother       Date:  2013-01-28       Impact factor: 3.452

8.  Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.

Authors:  John E Mindur; Naoko Ito; Suhayl Dhib-Jalbut; Kouichi Ito
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

9.  Mucosal Administration of E-selectin Limits Disability in Models of Multiple Sclerosis.

Authors:  Jacqueline A Quandt; Pierre Becquart; Emily Kamma; John Hallenbeck
Journal:  Front Mol Neurosci       Date:  2019-08-27       Impact factor: 5.639

10.  Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15.

Authors:  Lukas Simon Enz; Thomas Zeis; Daniela Schmid; Florian Geier; Franziska van der Meer; Guido Steiner; Ulrich Certa; Thomas Martin Christian Binder; Christine Stadelmann; Roland Martin; Nicole Schaeren-Wiemers
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.